The current financial score of Medifast Inc is 7.52. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 76.38M, representing a year-over-year decrease of 27.64%, while its net profit experienced a year-over-year decrease of 225.00%.
The current valuation score of Medifast Inc is 7.85. Its current P/E ratio is -6.56, which is -8339.55% below the recent high of 540.21 and -236.90% above the recent low of -22.09.
The current earnings forecast score of Medifast Inc is 6.00. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
The current price momentum score of Medifast Inc is 2.85. Currently, the stock price is trading between the resistance level at 12.75 and the support level at 11.44, making it suitable for range-bound swing trading.
The current institutional shareholding score of Medifast Inc is 7.00. The latest institutional shareholding proportion is 83.21%, representing a quarter-over-quarter decrease of 2.48%. The largest institutional shareholder is James Simons, holding a total of 778.61K shares, representing 0.01% of shares outstanding, with 37.27% decrease in holdings.
The current risk assessment score of Medifast Inc is 4.42. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.